Anti-Ro52 antibody levels and outlook in Sjögren's syndrome
Part of Immune system & allergy clinical trials.
This study looks at whether the level of a specific antibody (anti-Ro52) in your blood can predict how Sjögren's syndrome will progress. If you have Sjögren's and have had this blood test, the study may help doctors better understand your condition and tailor your care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years of age or older.
- You have been diagnosed with primary Sjögren's syndrome using standard criteria.
- You had a routine blood test for anti-Ro52 antibodies in 2020 or later.
- You are being followed by a doctor in a participating department (like internal medicine).
- You do not have other autoimmune diseases (except mild joint pain), no history of organ or bone marrow transplant, and no severe immune problems from other causes.
- Your medical records have enough information for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at an immune reaction (called anti-Ro/SSA IgE) to see how active primary Sjögren’s disease is. It may help doctors better understand what’s driving symptoms and activity levels over time.
This study tests an investigational drug called RSLV-132 in women with Sjögren's disease to see if it can reduce symptoms like fatigue and dryness. You may join if you've been diagnosed in the last 30 years and have persistent symptoms.
This study tests an experimental drug called DDY391 for people with Sjögren's disease. The goal is to see if it can reduce symptoms and improve quality of life, and to check for side effects.
This study follows people who have tested positive for Ro/SSA or La/SSB antibodies (proteins linked to certain autoimmune conditions). It also includes a control group of people without these antibodies or any rheumatologic disease. The goal is to learn more about long-term health patterns.
This Phase 2 study tests how to measure changes in primary Sjögren’s syndrome symptoms and body activity. It may help researchers confirm which outcomes best reflect improvement and how different patient types respond to treatment.
This study tests an investigational drug called CM336 for people with active Sjögren's syndrome. It aims to see if the drug is safe and effective in reducing symptoms like joint pain and dryness when other treatments haven't worked well.
Hear when a new Sjögren´s Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.